Compare Crocs, Inc. (CROX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Crocs, Inc. trades at $131.73 (market cap $6.63B), while DENTSPLY SIRONA Inc trades at $11.69 (market cap $2.32B). The key difference: Crocs, Inc. is far larger — about 2.9× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals.
| CROX | XRAY | |
|---|---|---|
Market Cap | $6.63B | $2.32B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $14.68 |
52-Week Low | $73.39 | $9.64 |
Enterprise Value | $8.14B | $4.40B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $136.62, up 1.82% with strong technical momentum and bullish moving averages. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $4.55 exceeding expectations. Despite a net loss in 2025 due to tax impacts, profitability metrics remain robust with 57.47% gross margins and 42.3% ROE. Recent news highlights tax strategy scrutiny but also strong DTC growth and raised 2026 guidance.
The stock presents value with a 12.12 P/E ratio below industry averages, supported by analyst consensus of $140.43 price target. Key risks include HEYDUDE brand weakness, tariff pressures, and ongoing tax scrutiny. Upside potential exists from international expansion and direct-to-consumer growth, though near-term volatility may persist around earnings.
DENTSPLY SIRONA (XRAY) trades at $12.12, down 7.97% in 24 hours, with a bearish technical signal and support near $12. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Financials show negative net income margins and ROE, though gross margins remain solid at 49.52%. Recent news highlights institutional stake increases and strategic partnerships, such as the expanded Medline Sinclair relationship in Canada.
The outlook is cautious due to persistent revenue declines and profitability challenges, offset by cost-cutting efforts and digital dentistry growth. Risks include weak European demand and high debt levels, while analyst consensus is Hold with a $11.50 price target, indicating limited near-term upside amid turnaround execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
